GB837465A - Self-propelling, powder-dispensing compositions - Google Patents

Self-propelling, powder-dispensing compositions

Info

Publication number
GB837465A
GB837465A GB2644/58A GB264458A GB837465A GB 837465 A GB837465 A GB 837465A GB 2644/58 A GB2644/58 A GB 2644/58A GB 264458 A GB264458 A GB 264458A GB 837465 A GB837465 A GB 837465A
Authority
GB
United Kingdom
Prior art keywords
propellant
less
composition
powder
specific gravity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB2644/58A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Riker Laboratories Inc
Original Assignee
Riker Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riker Laboratories Inc filed Critical Riker Laboratories Inc
Publication of GB837465A publication Critical patent/GB837465A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
    • A01N25/04—Dispersions, emulsions, suspoemulsions, suspension concentrates or gels
    • A01N25/06—Aerosols
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K3/00—Materials not provided for elsewhere
    • C09K3/30—Materials not provided for elsewhere for aerosols
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0043—For use with aerosol devices

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Materials Engineering (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Preparation (AREA)

Abstract

A self-propelling composition capable of dispensing a powder in aerosol form comprises a finely divided powder suspended in a mixture of a liquefied propellant having a b.p. less than 65 DEG F. at atmospheric pressure and a liquid non-ionic surface-active agent. The powder should have a substantially uniform particle size not greater than 100 microns, preferably less than 25 microns, constitute 0.01-20% by weight of the composition and desirably be insoluble in the surface-active agent-propellant mixture. Many medicines are specified as powders. Particularly for water-soluble powders the moisture content of the composition should be less than 300 parts per million by weight. The propellant is preferably a fluorinated or fluorochlorinated alkane containing not more than two carbon atoms and at least one fluorine atom, i.e. a "Freon." Other propellants are named. The surface-active agent should be preferably soluble in the propellant and constitute 0.1-20% by weight of the composition and have a hydrophile-lipophile balance (HLB) ratio of less than 10, preferably 1-5. Many surface-active agents are named, the sorbitan oleates being preferred. An anhydrous non-reactive desiccant, e.g. silica gel, may be incorporated in the composition. The specific gravity of the powder should be at least as great as the specific gravity of the propellant, and where the specific gravity of the medicinal ingredient is less than the specific gravity of the propellant an auxiliary solid (several specified) should be added. A formula is provided for the minimum amount of auxiliary solid required in such cases. The amount of auxiliary solid employed should be 1-10, preferably 1-3, times this minimum.
GB2644/58A 1957-01-31 1958-01-27 Self-propelling, powder-dispensing compositions Expired GB837465A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63735357A 1957-01-31 1957-01-31
US68001657A 1957-08-23 1957-08-23
US706908A US3014844A (en) 1957-01-31 1958-01-03 Self-propelling powder dispensing compositions

Publications (1)

Publication Number Publication Date
GB837465A true GB837465A (en) 1960-06-15

Family

ID=22180422

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2644/58A Expired GB837465A (en) 1957-01-31 1958-01-27 Self-propelling, powder-dispensing compositions

Country Status (6)

Country Link
US (1) US3014844A (en)
BE (1) BE556587A (en)
DE (1) DE1178975B (en)
FR (1) FR1228811A (en)
GB (1) GB837465A (en)
NL (2) NL106832C (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124505A (en) * 1964-03-10 Aerosol concentrates containing a sta-
FR2531972A1 (en) * 1980-03-17 1984-02-24 Riker Laboratories Inc SELF-PROPELLED AEROSOL COMPOSITION FOR POWDER DISPENSING AND PROCESS FOR PRODUCING THE SAME
WO1991004011A1 (en) * 1989-09-20 1991-04-04 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0460064A1 (en) * 1989-02-23 1991-12-11 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
EP0499344A2 (en) 1988-12-06 1992-08-19 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0563389A1 (en) * 1991-08-21 1993-10-06 ZHIRNOV, Oleg Petrovich Pharmaceutical aerosol preparation and its use for treatment and prophylaxis of viral diseases
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US6306440B1 (en) 1993-06-24 2001-10-23 Astrazeneca Ab Therapeutic preparation for inhalation
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US6743413B1 (en) 1991-12-18 2004-06-01 3M Company Suspension aerosol formulations
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7160538B2 (en) 1990-02-03 2007-01-09 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
US7994197B2 (en) 2007-02-11 2011-08-09 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8080236B2 (en) 2002-04-17 2011-12-20 Nektar Therapeutics Uk, Ltd Particulate materials
WO2013059409A1 (en) 2011-10-21 2013-04-25 3M Innovative Properties Company Manufacture of medicinal aerosol canisters
WO2013188609A1 (en) 2012-06-14 2013-12-19 3M Innovative Properties Company Metered dose dispensing valve
WO2014081746A1 (en) 2012-11-23 2014-05-30 3M Innovative Properties Company Metered dose dispensing valve
US9067031B2 (en) 2006-10-19 2015-06-30 3M Innovative Properties Company Metered dose valves and dispensers
US10335562B2 (en) 2006-07-24 2019-07-02 3M Innovative Properties Company Metered dose dispensers with porous body

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155573A (en) * 1958-05-06 1964-11-03 Benger Lab Ltd Inhalant composition and method of making same
US3076745A (en) * 1958-11-17 1963-02-05 Poultry Service And Res Corp Antibiotic method for promoting poultry growth
US3079299A (en) * 1959-11-16 1963-02-26 Gen Aerosol Corp Self-propelling medicinal ointment composition containing polyethylene and method ofapplication
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
DE1170909B (en) * 1961-02-17 1964-05-27 Specialties Dev Corp Self-propelling mixture
US3135658A (en) * 1961-10-10 1964-06-02 Merck & Co Inc Non-aqueous oleaginous aerosol foam therapy of bovine mastitis
US3095355A (en) * 1961-10-12 1963-06-25 Revlon Aerosol composition
GB1013386A (en) * 1962-05-01
BE632504A (en) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
BE629985A (en) * 1962-11-29
US3345295A (en) * 1963-02-13 1967-10-03 Shulton Inc Copper cleaning compositions
US3304230A (en) * 1963-02-18 1967-02-14 Revlon Liquid aerosol propellant solutions of fatty acid salts of physiologically active amines
US3446892A (en) * 1963-09-18 1969-05-27 Whitmire Research Lab Inc Immobilizing insects by sudden reduction of body temperature
US3260408A (en) * 1964-04-08 1966-07-12 Bell & Howell Co Method and means of dispersing particulate material in a stream of carrier fluid
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3968203A (en) * 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US3402665A (en) * 1966-08-15 1968-09-24 Aeroprojects Inc Nonpyrotechnic disseminator
US4027007A (en) * 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4411883A (en) * 1973-02-05 1983-10-25 Colgate-Palmolive Company Antiperspirant
US3923971A (en) * 1973-09-13 1975-12-02 Alexandre Seilinger Antiperspirant and deodorant composition containing lamellar substances
US4010252A (en) * 1974-12-19 1977-03-01 Colgate-Palmolive Company Antimicrobial compositions
US4192766A (en) * 1975-04-25 1980-03-11 United Chemical Corporation Composition for decreasing water resistance to movement
FI770215A (en) * 1976-01-30 1977-07-31 Fisons Ltd
US4147766A (en) * 1976-06-09 1979-04-03 Armour Pharmaceutical Company Macrospherical particles of anti-perspirants
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
DE2804931A1 (en) * 1978-02-06 1979-08-16 Fresenius Chem Pharm Ind METAL SULFADIAZINE IN FINE PARTICULAR FORM
JPS5529524A (en) * 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
CA1178889A (en) * 1980-08-28 1984-12-04 Kenneth S. Su Intranasal formulation
JPS59163313A (en) * 1983-03-09 1984-09-14 Teijin Ltd Peptide hormone composition for nasal administration
DE3326089A1 (en) * 1983-07-20 1985-02-07 Gödecke AG, 1000 Berlin INHALATION-INTENDED PHARMACEUTICAL FORM OF CALCIUM ANTAGONISTS
ZA852884B (en) * 1984-04-25 1986-11-26 Lilly Co Eli Sustained release intranasal formulation and method of use thereof
US4581225A (en) * 1984-04-25 1986-04-08 Eli Lilly And Company Sustained release intranasal formulation and method of use thereof
MX9203481A (en) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg FORMULATIONS.
HU205249B (en) * 1990-11-09 1992-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing suspensive aerosole composition
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
CA2125666C (en) 1991-12-12 2002-07-16 Rachel Ann Akehurst Medicaments
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
EP0616525B1 (en) * 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5756071A (en) * 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
US5368842A (en) * 1992-10-29 1994-11-29 The Gillette Company High efficacy aerosol antiperspirant composition
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
MX9704550A (en) 1994-12-22 1997-10-31 Astra Ab Aerosol drug formulations.
SE9404468D0 (en) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
DK1014943T3 (en) 1997-02-05 2002-10-14 Jago Res Ag Medical aerosol formulations
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US20010006939A1 (en) * 1997-10-03 2001-07-05 Ralph W. Niven Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
NZ509328A (en) 1998-07-24 2002-11-26 Jago Res A Medicinal aerosol formulations
ATE234604T1 (en) 1998-08-04 2003-04-15 Jago Res Ag MEDICAL AEROSOL FORMULATIONS
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
EP1949891A1 (en) 2004-10-12 2008-07-30 Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
WO2006040598A2 (en) * 2004-10-12 2006-04-20 Generics (Uk) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PT1901749T (en) 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
ES2809177T3 (en) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalation of levofloxacin to reduce lung inflammation
JP2012505223A (en) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド Aerosol fluoroquinolone formulation for improved pharmacokinetics
CA2773033C (en) 2009-09-04 2016-10-11 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
ES2913095T3 (en) 2011-01-31 2022-05-31 Avalyn Pharma Inc Aerosolized pirfenidone and pyridone analog compounds and uses thereof
WO2015017728A1 (en) 2013-07-31 2015-02-05 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
US9770443B2 (en) 2014-01-10 2017-09-26 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
GB2604314A (en) 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2440915A (en) * 1946-01-03 1948-05-04 Roberts Mfg Co Process for producing aerosols
US2524590A (en) * 1946-04-22 1950-10-03 Carsten F Boe Emulsion containing a liquefied propellant gas under pressure and method of spraying same
US2594296A (en) * 1948-06-24 1952-04-29 Aerosol Corp Lobeline aerosol dilating medicament
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor
GB764862A (en) * 1953-02-16 1957-01-02 Midland Silicones Ltd An article for dispensing organosilicon compounds
US2959325A (en) * 1954-04-29 1960-11-08 Risdon Mfg Co Method and apparatus for dispensing dry powders
US2782975A (en) * 1955-04-20 1957-02-26 American Cyanamid Co Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124505A (en) * 1964-03-10 Aerosol concentrates containing a sta-
FR2531972A1 (en) * 1980-03-17 1984-02-24 Riker Laboratories Inc SELF-PROPELLED AEROSOL COMPOSITION FOR POWDER DISPENSING AND PROCESS FOR PRODUCING THE SAME
GB2125426A (en) * 1980-03-17 1984-03-07 Riker Laboratories Inc Powder aerosol composition
US5720940A (en) * 1988-12-06 1998-02-24 Riker Laboratories, Inc. Medicinal aerosol formulations
US5681545A (en) * 1988-12-06 1997-10-28 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0499344A2 (en) 1988-12-06 1992-08-19 Riker Laboratories, Inc. Medicinal aerosol formulations
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US6352684B1 (en) 1988-12-06 2002-03-05 Riker Laboratories Inc. CRC-free medicinal aerosol formulations of 1,1,1,2-tetrafluoroethane (134A) with polar adjuvant
US5695743A (en) * 1988-12-06 1997-12-09 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0653204A2 (en) 1988-12-06 1995-05-17 Riker Laboratories, Inc. Medicinal aerosol formulations
US5683677A (en) * 1988-12-06 1997-11-04 Riker Laboratories, Inc. Medicinal aerosol formulations
US5605674A (en) * 1988-12-06 1997-02-25 Riker Laboratories, Inc. Medicinal aerosol formulations
US5674473A (en) * 1988-12-06 1997-10-07 Riker Laboratories, Inc. Medicinal aerosol formulations
EP0460064A4 (en) * 1989-02-23 1992-04-01 Rorer International (Holdings) Inc. Therapeutic aerosol formulations
EP0460064A1 (en) * 1989-02-23 1991-12-11 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
AU648994B2 (en) * 1989-09-20 1994-05-12 Riker Laboratories, Inc. Medicinal aerosol formulations
US5348730A (en) * 1989-09-20 1994-09-20 Minnesota Mining And Manufacturing Company Method for preparing medicinal aerosol formulation containing coated medicament
WO1991004011A1 (en) * 1989-09-20 1991-04-04 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US7160538B2 (en) 1990-02-03 2007-01-09 Boehringer Ingelheim Kg Suspension aerosol formulations of pharmaceutical products
EP0563389A4 (en) * 1991-08-21 1993-10-20 Oleg Petrovich Zhyrnov Pharmaceutical aerosol preparation and its use for treatment and prophylaxis of viral diseases
EP0563389A1 (en) * 1991-08-21 1993-10-06 ZHIRNOV, Oleg Petrovich Pharmaceutical aerosol preparation and its use for treatment and prophylaxis of viral diseases
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US6743413B1 (en) 1991-12-18 2004-06-01 3M Company Suspension aerosol formulations
US6306440B1 (en) 1993-06-24 2001-10-23 Astrazeneca Ab Therapeutic preparation for inhalation
US6846801B1 (en) 1993-06-24 2005-01-25 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5952008A (en) * 1993-06-24 1999-09-14 Ab Astra Processes for preparing compositions for inhalation
US6610653B1 (en) 1994-06-23 2003-08-26 Astrazeneca Ab Therapeutic preparation for inhalation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US6436902B1 (en) 1994-12-22 2002-08-20 Astrazeneca Ab Therapeutic preparations for inhalation
US8828359B2 (en) 2002-04-17 2014-09-09 Nektar Therapeutics Particulate materials
US8080236B2 (en) 2002-04-17 2011-12-20 Nektar Therapeutics Uk, Ltd Particulate materials
US10251881B2 (en) 2002-04-17 2019-04-09 Nektar Therapeutics Particulate materials
US9616060B2 (en) 2002-04-17 2017-04-11 Nektar Therapeutics Particulate materials
US8470301B2 (en) 2002-04-17 2013-06-25 Nektar Therapeutics Particulate materials
US10335562B2 (en) 2006-07-24 2019-07-02 3M Innovative Properties Company Metered dose dispensers with porous body
US9067031B2 (en) 2006-10-19 2015-06-30 3M Innovative Properties Company Metered dose valves and dispensers
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US9833451B2 (en) 2007-02-11 2017-12-05 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US10172853B2 (en) 2007-02-11 2019-01-08 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US8119639B2 (en) 2007-02-11 2012-02-21 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US7994197B2 (en) 2007-02-11 2011-08-09 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
WO2013059409A1 (en) 2011-10-21 2013-04-25 3M Innovative Properties Company Manufacture of medicinal aerosol canisters
US9694149B2 (en) 2011-10-21 2017-07-04 3M Innovative Properties Company Manufacture of medicinal aerosol canisters
WO2013188609A1 (en) 2012-06-14 2013-12-19 3M Innovative Properties Company Metered dose dispensing valve
WO2014081746A1 (en) 2012-11-23 2014-05-30 3M Innovative Properties Company Metered dose dispensing valve

Also Published As

Publication number Publication date
BE556587A (en) 1957-04-11
FR1228811A (en) 1960-09-02
NL106832C (en) 1963-12-16
NL224547A (en)
US3014844A (en) 1961-12-26
DE1178975B (en) 1964-10-01

Similar Documents

Publication Publication Date Title
GB837465A (en) Self-propelling, powder-dispensing compositions
US3169095A (en) Self-propelling powder-dispensing compositions
GR3030348T3 (en) Novel foaming compositions, particularly for rectal foams, and resulting foams
US3088874A (en) Powder aerosol
US3081223A (en) Self-propelled powder aerosol system
GB1450512A (en) Anhydrous candicidin foam compositions
PT96639A (en) Process for the preparation of a propellant composition containing fluorohydrocarbons
ZA98937B (en) Medicinal aerosol formulations
GB830426A (en) Self-propelling pharmaceutical compositions
JPS6129929B2 (en)
CA2355651A1 (en) Pharmaceutical aerosol formulations containing fluoroalkanes and budesonide
ES269650A1 (en) Silica-gel powder tablet compositions
GB969107A (en) Methylchloroform degreasing compositions
EP0047122A2 (en) Intranasal formulation
GB1013386A (en)
GB845916A (en) New fungicidal compositions
GB847476A (en) Improvements in or relating to compositions of matter suitable for the production of moulds
JPH0313275B2 (en)
GB963264A (en) Improvements in or relating to non-aqueous isoprenaline compositions
JP2772073B2 (en) Powder aerosol composition
ES397318A1 (en) Antiperspirant compositions
US3551558A (en) Therapeutical aerosol composition and preparation thereof
JPS6411615B2 (en)
GB800615A (en) Improvements in the preparation of aluminium sesquichlorides
ES275607A3 (en) A procedure for preparing a self-prompted composition for the dumping of dusts (Machine-translation by Google Translate, not legally binding)